Further SAR studies on novel small molecule inhibitors of the hepatitis C (HCV) NS5B polymerase

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 19, 2003, Pages 3341-3344

  Reddy, T Jagadeeswar ^a   Chan, Laval ^a   Turcotte, Nathalie ^a   Proulx, Melanie ^a   Pereira, Oswy Z ^a   Das, Sanjoy K ^a   Siddiqui, Arshad ^a   Wang, Wuyi ^a   Poisson, Carl ^a   Yannopoulos, Constantin G ^a   Bilimoria, Darius ^a   L'Heureux, Lucille ^a   Alaoui, Hicham M A ^a   Nguyen Ba, Nghe ^a  

^a Shire Canada   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; PHENYLALANINE DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG IDENTIFICATION; DRUG SELECTIVITY; ENZYME ACTIVE SITE; ENZYME INHIBITION; HEPATITIS C; IC 50; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

HEPATITIS C VIRUS;

EID: 10744225910     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00670-X     Document Type: Article

References (22)

1. (a) Memon M.I., Memon M.A. J. Viral. Hepat. 9:2002;84.
2. (b) Moradpour D., Cerny A., Heim M.H., Blum H.E. Swiss Med Weekly. 131:2001;291.
3. Idéo G., Bellobuono A. Curr. Pharm. Des. 8:2002;959.
4. (a) Wilkinson T. Curr. Opin. Invest. Drugs. 2:2001;1516.
5. (b) Orland, J. R., Wright, T. L., Cooper, S. Hepatology 2001, Feb, 321.
6. Rosenberg S. J. Mol. Biol. 313:2002;451.
7. (a) Dymock B.W. Emerg. Drugs. 6:2001;13
8. (b) HCV RNA-dependent RNA polymerase as a target for antiviral development: (i) Lai M.M.C. Antiviral Chem. Chemother. 12:2001;143. (ii) Walker, M. P.; Hong, Z. Curr. Opin. Pharm. 2002, 2, 1471.
9. (b) HCV RNA-dependent RNA polymerase as a target for antiviral development: (i) Lai M.M.C. Antiviral Chem. Chemother. 12:2001;143. (ii) Walker, M. P.; Hong, Z. Curr. Opin. Pharm. 2002, 2, 1471.
10. (c) . For a review on Non-structural protein inhibitors see: Beaulieu P.L., Llinas-Brunet M. Curr. Med. Chem.: Anti-Infect. Agents. 1:2002;163.
11. (a) For a review on recent patent literature, see: Zhang X. Idrugs. 5:2002;154.
12. (b) For recent paper on NS5B polymerase, see: Dhanak D., Duffy K.J., Johnston V.K., Lin-Goerke J., Darcy M., Shaw A.N., Gu B., Silverman C., Gates A.T., Nonnemacher M.R., Earnshaw D.L., Casper D.J., Kaura A., Baker A., Greenwood C., Gutshall L.L., Maley D., DelVecchio A., Macarron R., Hofmann G.A., Alnoah Z., Cheng H.-Y., Chan G., Khandekar S., Keenan R.M., Sarisky R.T. J. Biol. Chem. 277:2002;38322.
13. Information reported in Iddb3 from Current Drugs Ltd.
14. (a) For optimization of N-benzyl portion of 1 see: Chan L., Reddy T.J., Proulx M., Das S.K., Pereira O., Wang W., Siddiqui A., Yannopoulos C., Turcotte N., Drouin A., Alaouii H., Bethel R.C., Lucile H., Nguyen-Ba N. J. Med. Chem. 46:2003;1283.
15. (b) Ismaili, H.; Moulay, A.; Cheng, Y.-X.; Lavallee, J.-F.; Siddiqui, A. ; Storer, R. WO0160315, 2001 and US Patent 0019363, 2002.
16. (c) Wang M., Ng K. K.-S., Cherney M.M., Chan L., Yannopoulos C.G., Bedard J., Morin N., Nguyen-Ba N., Bethell R.C., James M.N.G. J. Biol. Chem. 278:2003;9489.
17. (a) Bressanelli S., Tomei L., Rey F.A., De Francesco R. J. Virol. 76:2002;3482 (rGTP binding site)
18. (b) During preparation of manuscript a patent on X-ray co-crstallization of inhibitors of an allosteric site of NS5B polymerase has appeared: Love, R. A.; Yu, X.; Diehl, W.; Hickey, M. J.; Parge, H. E.; Gao, J.; Fuhrman, S.; E. P. Patent 1256628 CAN 137:194827. Curr. Med. Chem.: Anti-Infect. Agents 2002, 1, 163.
19. 1H NMR spectra of test compounds also indicated the presence of numerous rotamers.
20. Ma D., Zhang Y., Yao J., Wu S., Tao F. J. Am. Chem. Soc. 120:1998;12459.
21. 2-Ethyl-4-chlorobenzoic acid was prepared from methyl 2-bromo-4-chlorobenzoic acid via a three step sequence employing vinyl Stille coupling, hydrogenation, and hydrolysis.
22. 50 value of a positive internal control was within standard deviation range.